^○Seigo Katakura¹, Shuji Murakami¹, Shinada Kanako¹, Ushio Ryota¹, Kondo Tetsuro¹, Kato Terufumi¹, Yokose Tomoyuki², Saito Haruhiro¹ (1.Department of Thoracic Oncology, Kanagawa Cancer Center, 2.Department of Pathology, Kanagawa Cancer Center)

^○Hiroaki Sakamoto¹, Hisashi Tanaka², Fumiyoshi Ohyanagi³, Yousuke Kawashima⁴, Yuichi Tambo⁵, Azusa Tanimoto⁶, Atsushi Horiike⁷, Eisaku Miyauchi⁸, Yuko Tsuchiya⁹, Makoto Nishio¹ (1.Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, 2.Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 3.Division of Pulmonary Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, 4.Department of Pulmonary Medicine, Sendai Kousei Hospital, 5.Department of Respiratory Medicine, Kanazawa University Hospital, 6.Division of Medical Oncology, Cancer Research Institute, Kanazawa University, 7.Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, 8.Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 9.Department of Respiratory Medicine, Kitakyushu Municipal Medical Center)

^○Satoru Miura¹, Martin Schuler², Sanjay Popat^3,4, Keunchil Park⁵, Antonio Passaro⁶, Filippo De Marinis⁶, Flavio Solca⁷, Angela Märten⁸, Edward S. Kim⁹, James Chih-Hsin Yang¹⁰ (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.West German Cancer Center, University Duisburg-Essen & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany, 3.Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom, 4.The Institute of Cancer Research, London, United Kingdom, 5.Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6.Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy, 7.Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria, 8.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 9.City of Hope National Medical Center, Los Angeles, CA, USA, 10.Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan)

^○Satoru Miura¹, Hyun Ae Jung², Shin Yup Lee³, Seung Hyeun Lee⁴, Min Ki Lee⁵, Yong Chul Lee⁶, Maximilian J Hochmair⁷, Cheng-Ta Yang⁸, Angela Märten⁹, James Chih-Hsin Yang¹⁰, Sanjay Popat^11,12 (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3.Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea, 4.Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, South Korea, 5.Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea, 6.Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk National Univers, 7.Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Vienna, Austria, 8.Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 9.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 10.Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, 11.Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom, 12.The Institute of Cancer Research, London, United Kingdom)

^○Akira Ono¹, Haruko Daga², Kyounghwa Bae³, Lyndah Dreiling³, Francois Lebel³, Koichi Goto⁴ (1.Head Physician Dept of Respiratory Medicine and Thoracic Oncology Shizuoka Cancer Center, 2.Director, Department of Medical Oncology, Osaka City General Hospital, 3.Spectrum Pharmaceuticals, Inc., 4.Chief, Department of Thoracic Oncology, National Cancer Center Hospital East Principal Investigator of LC-SCRUM-Asia)

^○Toshiaki Takahashi¹, Ferdinandos Skoulidis², Martin Schuler³, Jürgen Wolf⁴, Fabrice Barlesi⁵, Timothy J. Price⁶, Grace K. Dy⁷, Ramaswamy Govindan⁸, Hossein Borghaei⁹, Gerald Falchook¹⁰, Bob T. Li¹¹, Suresh Ramalingam¹², Adrian Sacher¹³, Alexander Spira¹⁴, Abraham Anderson¹⁵, Agnes Ang¹⁵, Tian Dai¹⁵, Donna Flesher¹⁵, Paul Cifuentes¹⁵, Vamsidhar Velcheti¹⁶ (1.Division of Thoracic Oncology, Shizuoka Cancer Center, 2.University of Texas M.D. Anderson Cancer Center, 3.West German Cancer Center, University Hospital Essen, 4.University Hospital Cologne, 5.Gustave Roussy Institute, 6.Queen Elizabeth Hospital and University of Adelaide, 7.Roswell Park Cancer Institute, 8.Alvin J. Siteman Cancer Center, Washington University School of Medicine, 9.Fox Chase Cancer Center, 10.Sarah Cannon Research Institute, 11.Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, 12.Winship Cancer Institute, Emory University School of Medicine, 13.Princess Margaret Cancer Centre, 14.Virginia Cancer Specialists and Johns Hopkins University, 15.Amgen Inc, 16.Perlmutter Cancer Center, NYU Langone)